BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 21871902)

  • 1. L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease.
    King JM; Muthian G; Mackey V; Smith M; Charlton C
    Life Sci; 2011 Oct; 89(17-18):638-43. PubMed ID: 21871902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of acute and sub-chronic L-dopa therapy on striatal L-dopa methylation and dopamine oxidation in an MPTP mouse model of Parkinsons disease.
    Smith ML; King J; Dent L; Mackey V; Muthian G; Griffin B; Charlton CG
    Life Sci; 2014 Aug; 110(1):1-7. PubMed ID: 24880075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine hydroxylase, aromatic L-amino acid decarboxylase and dopamine metabolism after chronic treatment with dopaminergic drugs.
    Cho S; Duchemin AM; Neff NH; Hadjiconstantinou M
    Brain Res; 1999 Jun; 830(2):237-45. PubMed ID: 10366680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SCH 23390 enhances exogenous L-DOPA decarboxylation in nigrostriatal neurons.
    Neff NH; Wemlinger TA; Hadjiconstantinou M
    J Neural Transm (Vienna); 2000; 107(4):429-43. PubMed ID: 11215754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.
    Riverol M; Ordóñez C; Collantes M; DiCaudo C; Peñuelas I; Arbizu J; Marcilla I; Luquin MR
    Neurobiol Dis; 2014 Feb; 62():250-9. PubMed ID: 24076099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cooperative synthesis of dopamine by non-dopaminergic neurons as a compensatory mechanism in the striatum of mice with MPTP-induced Parkinsonism.
    Kozina EA; Kim AR; Kurina AY; Ugrumov MV
    Neurobiol Dis; 2017 Feb; 98():108-121. PubMed ID: 27940203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Localization and functional significance of striatal neurons immunoreactive to aromatic L-amino acid decarboxylase or tyrosine hydroxylase in rat Parkinsonian models.
    Lopez-Real A; Rodriguez-Pallares J; Guerra MJ; Labandeira-Garcia JL
    Brain Res; 2003 Apr; 969(1-2):135-46. PubMed ID: 12676374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L; Frohna PA; Joyce JN; Schneider JS
    Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clozapine modulates aromatic L-amino acid decarboxylase activity in mouse striatum.
    Neff NH; Wemlinger TA; Duchemin AM; Hadjiconstantinou M
    J Pharmacol Exp Ther; 2006 May; 317(2):480-7. PubMed ID: 16415089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing aromatic L-amino acid decarboxylase activity: implications for L-DOPA treatment in Parkinson's disease.
    Hadjiconstantinou M; Neff NH
    CNS Neurosci Ther; 2008; 14(4):340-51. PubMed ID: 19040557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
    Atlas D
    CNS Neurosci Ther; 2016 Jun; 22(6):461-7. PubMed ID: 26861609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to mice on tyrosine hydroxylase, L-3,4-dihydroxyphenylalanine decarboxylase, dopamine beta-hydroxylase, and monoamine oxidase activities in the striatum and hypothalamus.
    Mogi M; Harada M; Kojima K; Kiuchi K; Nagatsu T
    J Neurochem; 1988 Apr; 50(4):1053-6. PubMed ID: 2894407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
    Naskar A; Prabhakar V; Singh R; Dutta D; Mohanakumar KP
    J Pineal Res; 2015 Apr; 58(3):262-74. PubMed ID: 25626558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial.
    Ciesielska A; Samaranch L; San Sebastian W; Dickson DW; Goldman S; Forsayeth J; Bankiewicz KS
    PLoS One; 2017; 12(2):e0169965. PubMed ID: 28166239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys.
    Huot P; Lévesque M; Morissette M; Calon F; Dridi M; Di Paolo T; Parent A
    J Chem Neuroanat; 2008 Jan; 35(1):77-84. PubMed ID: 17706922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The roles of striatal serotonin and L -amino-acid decarboxylase on L-DOPA-induced Dyskinesia in a Hemiparkinsonian rat model.
    Gil S; Park C; Lee J; Koh H
    Cell Mol Neurobiol; 2010 Aug; 30(6):817-25. PubMed ID: 20232137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanomolar L-dopa facilitates release of dopamine via presynaptic beta-adrenoceptors: comparative studies on the actions in striatal slices from control and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mice, an animal model for Parkinson's disease.
    Goshima Y; Misu Y; Arai N; Misugi K
    Jpn J Pharmacol; 1991 Jan; 55(1):93-100. PubMed ID: 1645816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of (-)-sesamin on motor and memory deficits in an MPTP-lesioned mouse model of Parkinson's disease treated with l-DOPA.
    Zhao TT; Shin KS; Kim KS; Park HJ; Kim HJ; Lee KE; Lee MK
    Neuroscience; 2016 Dec; 339():644-654. PubMed ID: 27789382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nigrostriatal reduction of aromatic L-amino acid decarboxylase activity in MPTP-treated squirrel monkeys: in vivo and in vitro investigations.
    Yee RE; Huang SC; Stout DB; Irwin I; Shoghi-Jadid K; Togaski DM; DeLanney LE; Langston JW; Satyamurthy N; Farahani KF; Phelps ME; Barrio JR
    J Neurochem; 2000 Mar; 74(3):1147-57. PubMed ID: 10693947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CaMKII inhibition ameliorated levodopa-induced dyskinesia by downregulating tyrosine hydroxylase activity in an experimental model of Parkinson's disease.
    Yang X; Zhu Z; Ding X; Wang X; Cui G; Hua F; Xiang J
    Brain Res; 2018 May; 1687():66-73. PubMed ID: 29452071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.